Anistreplase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anistreplase
Clinical data
Trade names Eminase
AHFS/Drugs.com Micromedex Detailed Consumer Information
ATC code
Pharmacokinetic data
Biological half-life 90 minutes
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
KEGG
Chemical and physical data
Molar mass approx. 131 kg/mol
  (verify)

Anistreplase is a thrombolytic drug.[1][2][3]

Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)

Mechanism[edit]

It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.

References[edit]